BSN723T Prevents Atherosclerosis and Weight Gain in ApoE Knockout Mice Fed a Western Diet.
OBJECTIVE
This study tests the hypothesis that BSN723T can prevent the development of hyperlipidemia and atherosclerosis in ApoE-/-knockout mice fed a Western (high fat, high cholesterol, and high sucrose) diet. BSN723T is a combination drug therapy consisting of D-tagatose and dihydromyricetin (BSN723).


BACKGROUND
D-tagatose has an antihyperglycemic effect in animal and human studies and shows promise as a treatment for type 2 diabetes and obesity. Many claims regarding BSN723's pharmacological activities have been made including anti-cancer, anti-diabetic, anti-hypertensive, anti-inflammatory, and anti-atherosclerotic effects. To our knowledge this is the first study that combines D-tagatose and BSN723 for the treatment of hyperlipidemia and the prevention of atherosclerosis.


METHODS
ApoE-deficient mice were randomized into five groups with equivalent mean body weights. The mice were given the following diets for 8 weeks: Group 1 - Standard diet; Group 2 - Western diet; Group 3 - Western diet formulated with D-tagatose; Group 4 - Western diet formulated with BSN723; Group 5 - Western diet formulated with BSN723T. Mice were measured for weight gain, tissue and organ weights, total serum cholesterol and triglycerides and formation of atherosclerosis.


RESULTS
The addition of D-tagatose, either alone or in combination with BSN723, prevented the increase in adipose tissue and weight gain brought on by the Western diet. Both D-tagatose and BSN723 alone reduced total cholesterol and the formation of atherosclerosis in the aorta compared to mice on the Western diet. Addition of BSN723 to D-tagatose (BSN723T) did not increase efficacy in prevention of increases in cholesterol or atherosclerosis compared to D-tagatose alone.


CONCLUSIONS
Addition of either D-tagatose or BSN723 alone to a Western diet prevented weight gain, increases in total serum cholesterol and triglycerides, and the formation of atherosclerosis. However, there was no additive or synergistic effect on the measured parameters with the combination BSN723T treatment.
University of Kentucky, Department of Pharmaceutical Sciences - United States of America.
Jarrod
J
Williams
University of Kentucky, Department of Pharmaceutical Sciences - United States of America.
Charles
C
Ensor
University of Bath - United Kingdom.
Scott
S
Gardner
University of Kentucky, Department of Pharmaceutical Sciences - United States of America.
Rebecca
R
Smith
Pharmaceutical Sciences, BPC223 Biopharmaceutical Complex, 40536 - United States of America.
Robert
R
Lodder
ApoE-/-; D-lyxohexulose; D-tagatose; DLH; atheroma; dihydromyricetin; fat; sucrose
Am J Clin Nutr. 1992 Apr;55(4):851-6
1550068
Oncotarget. 2015 Feb 20;6(5):3254-67
25226612
J Endocrinol Diabetes Obes. 2014 Oct;2(4):1057
25580449
Regul Toxicol Pharmacol. 1999 Apr;29(2 Pt 2):S57-65
10341162
Diabetes. 1993 Mar;42(3):457-62
8432416
Arch Pharm Res. 2008 Aug;31(8):978-82
18787784
Biochem J. 1994 Feb 15;298 ( Pt 1):237-43
8129726
J Sci Food Agric. 2015 Jun;95(8):1584-97
25171728
Arterioscler Thromb. 1994 Jan;14(1):133-40
8274468
Med Sci Sports Exerc. 2014 Nov;46(11):2077-84
24637344
J Dev Drugs. 2013 Oct;2(2):null
25866829
Arterioscler Thromb Vasc Biol. 2001 Dec;21(12):2032-8
11742881
Science. 1992 Oct 16;258(5081):468-71
1411543
Sci Rep. 2014 Nov 13;4:7041
25391369
Annu Rev Nutr. 1995;15:495-518
8527231
J Clin Invest. 2006 Dec;116(12):3090-100
17143322
Nature. 2006 Dec 14;444(7121):881-7
17167477
Yao Xue Xue Bao. 2003 Apr;38(4):241-4
12889119
Diabetes Care. 2006 Jun;29(6):1220-6
16731999
Obesity (Silver Spring). 2009 Feb;17 (2):269-75
19008872
Arterioscler Thromb Vasc Biol. 1999 May;19(5):1223-30
10323773
Circulation. 2007 Sep 18;116(12 ):1338-40
17875978
Brain Res Bull. 2014 Oct;109:117-26
25451453
J Agric Food Chem. 2012 Aug 1;60(30):7435-41
22762395
Hypertension. 1994 Apr;23(4):456-63
8144215
Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13294-9
11606787
J Endocrinol Invest. 2006;29(3 Suppl):77-82
16751711
J Chromatogr A. 2002 Oct 11;973(1-2):217-20
12437181
J Biol Chem. 1996 Sep 27;271(39):23756-60
8798601
Atherosclerosis. 1979 Jul;33(3):301-14
114194
J Endocrinol Diabetes Obes. 2015;3(1):null
27054147
Int Immunopharmacol. 2012 Jan;12(1):278-87
22193240
Planta Med. 2008 Feb;74(3):252-7
18300190
Regul Toxicol Pharmacol. 1999 Apr;29(2 Pt 2):S36-42
10341159
Anticancer Drugs. 2012 Jul;23(6):590-6
22241170
Arterioscler Thromb. 1994 Jan;14(1):141-7
8274470
Nutr Res. 2010 Dec;30(12 ):801-6
21147362
Neurochem Res. 2014 Jun;39(6):1171-81
24728903
Regul Toxicol Pharmacol. 1999 Apr;29(2 Pt 2):S1-10
10341156
PLoS One. 2012;7(6):e38802
22693649
Zhong Yao Cai. 2004 Nov;27(11):842-5
15810594
Circulation. 1997 Jun 3;95(11):2591-3
9184593
Oncol Rep. 2014 Jun;31(6):2713-9
24789439
Arterioscler Thromb Vasc Biol. 2001 Mar;21(3):365-71
11231915
Diabetes Obes Metab. 2008 Feb;10 (2):109-34
17941870
Endocrine. 2015 Nov;50(2):378-89
25896550
Mol Med Rep. 2015 Jan;11(1):105-12
25333250
Pharmacol Res. 2015 Sep;99:74-81
26032587
Mol Cell Endocrinol. 2015 Sep 5;412:349-57
26054747
Sci Rep. 2014 Apr 10;4:4628
24717393
Rocz Panstw Zakl Hig. 2014;65(2):79-85
25272572
Br J Nutr. 2001 Mar;85 Suppl 1:S7-16
11321031
J Neurosci. 2012 Jan 4;32(1):390-401
22219299
J Lipid Res. 2006 Oct;47(10):2215-22
16840797
Mol Cell Endocrinol. 2015 Jul 5;409:92-102
25797177
Cancer Prev Res (Phila). 2014 Sep;7(9):927-38
24894198
Eur J Biochem. 1989 Jan 15;179(1):173-7
2917559
Rejuvenation Res. 2014 Oct;17 (5):422-9
24835723
Diabetes Obes Metab. 1999 Sep;1(5):285-91
11225640
World J Gastroenterol. 2014 Aug 7;20(29):10082-93
25110435
Regul Toxicol Pharmacol. 1999 Apr;29(2 Pt 2):S29-35
10341158
Am J Clin Nutr. 2007 Jun;85(6):1511-20
17556686